Oncolytic viruses and cancer therapy

Cytokine and Growth Factor Reviews

Volumn 12, Issue 2-3, 2001, Pages 271-282

  Norman, Kara L ^a   Farassati, Faris ^a   Lee, Patrick W K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adenovirus; Cancer; Herpesvirus; Oncolysis; Reovirus; VSV

Indexed keywords

ADENOVIRUS; ANIMAL; CANCER THERAPY; DNA VECTOR; HERPES SIMPLEX VIRUS; HUMAN; NEOPLASM; NONHUMAN; ONCOLYTIC VIRUS; REOVIRUS; REVIEW; SEROTYPE; VESICULAR STOMATITIS VIRUS; VIRUS; VIRUS REPLICATION; VIRUS TYPING;

ADENOVIRIDAE; ANIMALS; GENETIC VECTORS; HUMANS; NEOPLASMS; REOVIRIDAE; SIMPLEXVIRUS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUSES;

ADENOVIRIDAE; ANIMALIA; HERPES; HERPESVIRIDAE; REOVIRUS SP.; SIMPLEXVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0034953131     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(00)00024-1     Document Type: Review

References (89)

1. New developments in the virus therapy of cancer: A historical review
2. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection
3. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus
4. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein
5. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
6. Studies on the use of viruses in the treatment of carcinoma of the cervix
7. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
8. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
9. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
10. The p53 tumour suppressor gene
11. p53 mutations in human cancers
12. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
13. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
14. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
15. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
16. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
17. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
18. Killing tumor cells with viruses-A question of specificity
19. ONYX-015: Clinical data are encouraging
20. The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2
21. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53
22. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function
23. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells
24. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells
25. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence
26. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport
27. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
28. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
29. Replication-selective adenoviruses as oncolytic agents
30. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
31. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen
32. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
33. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
34. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
35. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts
36. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
37. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virustk: Assessment of antitumor efficacy and toxicity
38. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
39. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
40. Cancer cell cycles
41. The preferential cytotoxicity of reovirus for certain transformed cell lines
42. Differential sensitivity of normal and transformed human cells to reovirus infection
43. Enzymatic and control functions of reovirus structural proteins
44. Neutralization of reovirus: The gene responsible for the neutralization antigen
45. Reoviruses
46. Reovirus infections in human volunteers
47. Reoviruses: A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described
48. Viruses causing common respiratory infection in man. IV. Reoviruses and adenoviruses
49. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease
50. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis
51. The alpha-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus
52. Reovirus binds to multiple plasma membrane proteins of mouse L fibroblasts
53. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency
54. Mechanism of interferon action. Activation of the human P1/eIF-2 alpha protein kinase by individual reovirus s-class mRNAs: S1 mRNA is a potent activator relative to s4 mRNA
55. A GDP/GTP exchange factor essential for eukaryotic initiation factor 2 cycling in Ehrlich ascites tumor cells and its regulation by eukaryotic initiation factor 2 phosphorylation
56. Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation
57. Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells
58. Reovirus therapy of tumors with activated Ras pathway
59. Herpes simplex viruses
60. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family
61. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors
62. Capsid assembly and DNA packaging in herpes simplex virus
63. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
64. Conditionally replicating herpes vectors for cancer therapy
65. The double-stranded RNA-dependent protein kinase PKR: Structure and function
66. Herpes simplex virus virulence: The functions of the gamma (1)34.5 gene
67. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase
68. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
69. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors
70. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
71. A synthetic inhibitor of the mitogen-activated protein kinase cascade
72. Farnesyltransferase inhibitors versus Ras inhibitors
73. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
74. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase
75. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
76. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates
77. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207
78. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
79. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium, and is suitable for intraperitoneal oncolytic therapy
80. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1
81. Local and systemic therapy of human prostate cancer with the conditionally replicating herpes simplex virus vector G207
82. Replication-competent herpes simplex virus vector G207/cisplatin combination therapy for head and neck squamous cell carcinoma
83. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant
84. Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus
85. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer
86. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
87. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
88. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus
89. PKR; a sentinel kinase for cellular stress